Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Linda Sandin"'
Autor:
Linda Sandin, Amanda von Below, Maria Waller, Cecilia Björkelund, Ann Blomstrand, Rebecca Runevad, Dominique Hange
Publikováno v:
Scandinavian Journal of Primary Health Care, Vol 41, Iss 3, Pp 214-223 (2023)
AbstractAim To investigate trends in the haemoglobin (Hb) level in middle-aged Swedish women from 1968 to 2017 and to examine the potential association between Hb and the use of hormonal contraceptives (HCs).Design A prospective observational populat
Externí odkaz:
https://doaj.org/article/18264aded7c242ac98ea67fbf1fbac02
Autor:
Amanda Hahn, Sandra Irenaeus, Jessica Wenthe, Emma Eriksson, Aglaia Schiza, Hanna Dahlstrand, Ulla Olsson-Strömberg, Johan Krause, Anders Sundin, Linda Sandin, Justyna Leja Jarblad, Maria Gustafsson Liljefors, Eric Rowinsky, Angelica Loskog, Gustav J. Ullenhag
Publikováno v:
Cancer Research. 83:CT235-CT235
There is a need for therapeutics with novel mechanisms-of-action for patients with advanced solid malignancies. In this first completed part of LOKON002, a phase I/II (NCT03225989) clinical study, the safety and clinical response to LOAd703 in combin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d0346e73b11808d75e0923a5de46225
https://doi.org/10.1158/1538-7445.am2023-ct235
https://doi.org/10.1158/1538-7445.am2023-ct235
Autor:
Jessica Wenthe, Emma Eriksson, Sedigheh Naseri, Linda Sandin, Amanda Hahn, Sandra Irenaeus, Anders Sundin, Justyna Leja-Jarblad, Gustav Ullenhag, Tanja Lövgren, Angelica Loskog
Publikováno v:
Cancer Research. 83:6663-6663
In the LOKON002 phase I/II clinical trial (NCT03225989), therapy with LOAd703 (delolimogene mupadenorepvec) is investigated in combination with gemcitabine-based chemotherapy in patients with advanced cancer. LOAd703 is an immunostimulatory gene ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb7d6ce2301c7ea919bbe16c1ca797ae
https://doi.org/10.1158/1538-7445.am2023-6663
https://doi.org/10.1158/1538-7445.am2023-6663
Autor:
Vikki Flemington, Elizabeth A. Coker, Patricia Jaaks, Linda Sandin, Philip Hopcroft, Nicola Lindsay, Aaron Smith, Lyndsey Hanson, David Robinson, Clifford David Jones, Mathew J. Garnett, Karen Roberts, Francis D. Gibbons, Stephen Fawell, Richard A. Ward, Sabina Cosulich, Iain Simpson, Emma J. Davies, Oona Delpuech, J. Elizabeth Pease, Paul D. Smith, Martine P. Roudier, Claire Rooney, Katarzyna Falenta, Joanne Wilson, Sophie E. Willis, Sigourney Bell, Paul Farrington, Michael Tonge, Pei Zhang
Publikováno v:
Molecular Cancer Therapeutics. 20:238-249
The RAS-regulated RAF–MEK1/2–ERK1/2 (RAS/MAPK) signaling pathway is a major driver in oncogenesis and is frequently dysregulated in human cancers, primarily by mutations in BRAF or RAS genes. The clinical benefit of inhibitors of this pathway as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05d9f9feac6e1234051a1b9a7d32a736
https://doi.org/10.1158/1535-7163.mct-20-0002
https://doi.org/10.1158/1535-7163.mct-20-0002
Publikováno v:
Menopause. 27:430-436
Objective The aim of this study was to examine if the previously found trend of increasing menopausal age is continuing, taking into consideration hormonal use and surgical menopause in both 38- and 50-year-old women of today. Methods Cohort comparis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::919cf8f8d019099942438ef1f2a921b1
https://doi.org/10.1097/gme.0000000000001476
https://doi.org/10.1097/gme.0000000000001476
Autor:
Benjamin Leon Musher, Brandon George Smaglo, Wasif Abidi, Mohamed Othman, Kalpesh Patel, Salmaan Jawaid, James Jing, Amanda Brisco, Jessica Wenthe, Emma Eriksson, Gustav J. Ullenhag, Linda Sandin, Bambi Grilley, Justyna Leja-Jarblad, Susan G. Hilsenbeck, Malcolm K. Brenner, Eric Keith Rowinsky, Angelica Sara Ingrid Loskog
Publikováno v:
Journal of Clinical Oncology. 40:4138-4138
4138 Background: Due to its low tumor immunogenicity and immunosuppressive microenvironment, pancreatic ductal adenocarcinoma (PDAC) remains an immunotherapeutic challenge. LOAd703, an oncolytic adenovirus with transgenes encoding TMZ-CD40L and 4-1BB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::093c77a30caf8a6f2434cb829d2cbeb6
https://doi.org/10.1200/jco.2022.40.16_suppl.4138
https://doi.org/10.1200/jco.2022.40.16_suppl.4138
Autor:
Lukasz Magiera, Linda Sandin, Anna Staniszewska, Simon T. Barry, Josephine Walton, Amanda Watkins, Larissa S. Carnevalli, Lorraine Mooney, Sigourney Bell, A. Hughes, Anna M. L. Coenen-Stass, Elizabeth Hardaker, Molly A. Taylor
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background The ability to modulate immune-inhibitory pathways using checkpoint blockade antibodies such as αPD-1, αPD-L1, and αCTLA-4 represents a significant breakthrough in cancer therapy in recent years. This has driven interest in identifying
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0da3386da8287fd725c2d3b476acd767
https://doi.org/10.1186/s40425-019-0794-7
https://doi.org/10.1186/s40425-019-0794-7
Autor:
Jia Tang, Richard A. Ward, Paul A. Bethel, Scott G. Lamont, Julian A. Hudson, Philip Hopcroft, Clifford David Jones, Steve Swallow, Richard J. Lewis, Tomkinson Gary Peter, Baochang Zhai, Nicola Lindsay, Jason Breed, Emma J. Davies, Yongchao Li, Vikki Flemington, Michael Tonge, Paul Farrington, Ryan Greenwood, Mark A. Graham, Linda Sandin, Thomas M. McGuire, James F. McCabe, Mark J. Anderton, Michael R. James, Andrew Hornby Dobson, Philip B. Rawlins, Lyndsey Hanson, Iain Simpson, Karen Roberts, Gary Fairley, Rachel L. Howells, Christopher R. Jones, Calum Cook, Francis D. Gibbons, Zhiqiang Dong, Lyman Feron, Zhenhua Wang
Publikováno v:
Journal of medicinal chemistry. 62(24)
The RAS/MAPK pathway is a major driver of oncogenesis and is dysregulated in approximately 30% of human cancers, primarily by mutations in the BRAF or RAS genes. The extracellular-signal-regulated kinases (ERK1 and ERK2) serve as central nodes within
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68575e1f1cd6f592b8ead892c32d4cc6
https://pubmed.ncbi.nlm.nih.gov/31710489
https://pubmed.ncbi.nlm.nih.gov/31710489
Autor:
Paul Farrington, J. Elizabeth Pease, Linda Sandin, Lyndsey Hanson, Rebecca Whiteley, Emma J. Davies, Francis D. Gibbons, Vikki Flemington, Nicola Lindsay
Publikováno v:
Cancer Research. 78:4913-4913
ERK1/2 is a key protein in the MAPK pathway, regulating phenotypes such as proliferation and migration. Upstream mutations (e.g., KRAS mutations in non-small-cell lung (NSCLC)) can cause the pathway to become constitutively activated, driving tumor g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8816aae3a99cf6cd5247c5d27fa071e8
https://doi.org/10.1158/1538-7445.am2018-4913
https://doi.org/10.1158/1538-7445.am2018-4913
Autor:
Linda Sandin, Jason Breed, Emma J. Davies, David Robinson, Clifford David Jones, Elizabeth Janet Pease, Richard A. Ward, Pei Zhang, Karen Roberts, Francis D. Gibbons, Claire Rooney, Nicola Lyndsay, Iain Simpson, Phillip Hopcroft, Vikki Flemington, Christopher G Jones
Publikováno v:
Cancer Research. 78:1856-1856
The RAS/MAPK pathway is a major driver in oncogenesis and is dysregulated in approximately 30% of human cancers, primarily by mutations in BRAF or RAS genes. While BRAF and MEK inhibitors improve BRAF mutant melanoma patient outcomes, single-agent pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82a6c5c063b3235f68c74fdb840dbd15
https://doi.org/10.1158/1538-7445.am2018-1856
https://doi.org/10.1158/1538-7445.am2018-1856